About D-NOME
D-NOME is a Healthcare company based in Hyderabad (India) founded in 2021 by Sujoy Deb and Divya Sriram. D-NOME has raised $1.56 million across 3 funding rounds from investors including LetsVenture, Ankur Capital and Campus Fund. The company has 1 employees. D-NOME was last valued at $6.15 million in December 2022. Its Indian entity D-Nome Private Limited reported revenue of ₹2.15 Cr. D-NOME offers products and services including Diagnostics Platform. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its competitors include ArcherDX, Sino Biological, GenScript, OncoDNA and Fluent BioSciences and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Developer of reagents and kits for molecular diagnostics. The company develops diagnostic reagents based on proprietary, innovative reagent technologies for genomic applications. The product line includes D-LAMP PCR enzyme mix and D-LAMP genome sequencing reagent.
- Headquarters Hyderabad, India
- Employees 1
- Founders Sujoy Deb, Divya Sriram
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Website dnome.in
- Social LinkedIn
- Legal Name D-Nome Private Limited
- Date of Incorporation 20 Jul, 2021
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹2.15 Cr
FY 2025 · +76% YoY
- Net Loss-₹1.4 Lakh
FY 2025 · -1% margin
- EBITDA₹2.1 Lakh
FY 2025 · 1% margin
- Total Equity Funding$1.56M (USD)
in 3 rounds
- Latest Funding Round$1.5M (USD), Seed
Dec 2022
- InvestorsLetsVenture
& 13 more
- Employee Count1
Associated legal entities of D-NOME
D-NOME operates through D-Nome Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| D-Nome Private Limited CIN U33100TG2021PTC153287 | Active | 20 Jul 2021 | Hyderabad, Telangana | ₹2.2 Cr | 430 | 2 | View details |
Products & Services of D-NOME
D-NOME offers a comprehensive portfolio of products and services, including Diagnostics Platform.
Enables rapid and accurate molecular diagnostics using synthetic tech.
Funding Insights of D-NOME
D-NOME has successfully raised a total of $1.56M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.5 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.56M
- Total Rounds 3
- Last Round Seed — $1.5M
- First Round $57,487
(Sep 2021)
- Investors Count 14
All 3 funding rounds of D-NOME with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $1.5M | Seed | $6.15M | Ankur Capital, Campus Fund | |
| Dec 2021 | – | Grant | – | – | |
| Sep 2021 | $57,487 | Seed | $623,121 | Entrepreneur First | – |
| Date | Valuation | Stage |
|---|---|---|
| Dec 2022 | $6.15M | •••••••• |
Last known valuation $6.15M (Dec 2022). 14 investors in total: 9 institutional and 5 angel.
Investors in D-NOME
D-NOME has secured backing from 14 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include LetsVenture, Ankur Capital and Campus Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in digital, climate, and deep science technologies. | 2011 | ankurcapital.com | Mumbai, India | |
Student-led startups are invested in by this venture capital firm. | – | yourcampusfund.com | Bengaluru, India | |
Venture capital firm investing in multiple sectors | – | 8xventures.co | Dubai, United Arab Emirates | |
Micro venture capital fund focusing on health tech sector | – | lvangelfund.tcc.mode | Bengaluru, India | |
Private equity investments are focused on multiple sectors. | – | truestartadvisory.tcc.mode | Thane, India | |
- | – | 3ipartners.vc | - | |
Provider of a program turning individuals into funded technology company founders | – | joinef.com | London, United Kingdom | |
Online platform that connects startup founders with accredited investors, enabling early-stage fundraising and investment opportunities for private market growth | 2013 | letsventure.com | Bengaluru, India | |
- | – | nationalbioentrepreneurship.in | - | |
SC Shalini Chhabra | Angel investor focusing on early-stage Indian startups in tech and consumer sectors. | – | unknown_deebb4b8d2ce421ca | - |
Investor details for D-NOME
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of D-Nome Private Limited (D-NOME)
D-Nome Private Limited is the primary company behind D-NOME. The board of D-Nome Private Limited currently have 2 directors; the longest-serving is Divya Sriram, appointed in 2021.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Divya Sriram DIN 09246447 | Director | 20 Jul 2021 | 5 yrs 3 mo | D-Nome Private Limited |
| Sujoy Deb DIN 09246448 | Director | 20 Jul 2021 | 5 yrs 3 mo | D-Nome Private Limited |
People of D-NOME
2 people are tracked at D-NOME (2 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
| Co-Founder & CTO | Leadership | |
| Co-Founder | Leadership |
Complete people profiles for D-NOME
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of D-NOME
Figures of D-Nome Private Limited, the primary company behind D-NOME, for FY 2025. Revenue was ₹2.15 Cr (+76% year on year). Net loss was -₹1.4 Lakh (-1% margin). EBITDA was ₹2.1 Lakh (1% margin). Revenue has grown at a compounded annual rate of +114% over three years.
- ₹2.15 CrRevenue · FY 2025 · +76% YoY
- -₹1.4 LakhNet loss · -1% margin
- ₹2.1 LakhEBITDA · 1% margin
- ₹1.6 LakhPaid-up capital
- 430Employees (provident fund records)
- +114%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of D-Nome Private Limited are on its company page.
Detailed financial statements for D-NOME
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of D-NOME
4 dated milestones of D-NOME across 1 years, from founding to its latest funding, stage changes and deals.
- Founded D-NOME is founded.
- Funding First funding round of $57K.
- Funding Latest funding round, Seed, of $1.5M.
- Milestone Reaches Minicorn status.
Competitors of D-NOME
D-NOME has 10 listed competitors in our database, 8 of them funded. They include ArcherDX, Sino Biological, GenScript, OncoDNA and Fluent BioSciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| inscripta.io | 2015 | Helsinki, Finland | $853,384 | – | Speech recognition solutions are provided by Inscripta for healthcare professionals. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| diagenode.com | 2003 | Seraing, Belgium | $8.45M | 99 | Reagents and kits for epigenetics sequencing solutions are developed. |
Detailed competitors of D-NOME
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as D-NOME (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about D-Nome
Complete news archive for D-NOME
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about D-NOME
D-NOME was founded in 2021.
D-NOME is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
D-NOME is a funded company, having raised a total of $1.56M across 3 funding rounds to date. The company's 1st funding round was a Seed of $57.49K, raised on Sep 2021.
D-NOME has 1 employees.
The primary company behind D-NOME, D-Nome Private Limited, reported revenue of ₹2.15 Cr for FY 2025, up 76% year on year.
Developer of reagents and kits for molecular diagnostics. The company develops diagnostic reagents based on proprietary, innovative reagent technologies for genomic applications. The product line includes D-LAMP PCR enzyme mix and D-LAMP genome sequencing reagent.
D-NOME's top competitors include Sino Biological, OncoDNA and ArcherDX.
D-NOME offers Diagnostics Platform.
D-NOME has 14 investors. Key investors include LetsVenture, Ankur Capital, Campus Fund, 8X Ventures, and LV Angel Fund.
The valuation of D-NOME is $6.15M as of Dec 2022.
D-NOME operates through D-Nome Private Limited.
The legal entities of D-NOME currently have 2 directors, including Divya Sriram, Sujoy Deb.